| 1 |
32276526 | Cytochrome P450 (CYP450) Interactions Involving Atypical Antipsychotics are Common in Community-Dwelling Older Adults Treated for Behavioral and Psychological Symptoms of Dementia. | 2020 Apr 8 |
1 |
| 2 |
26952092 | Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. | 2016 Jun |
1 |
| 3 |
25499431 | Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein. | 2015 Jan 15 |
9 |
| 4 |
24107805 | Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease. | 2014 |
1 |
| 5 |
24433464 | Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. | 2014 Jul |
1 |
| 6 |
23408070 | Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. | 2013 Apr |
1 |
| 7 |
22372724 | Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study. | 2012 Mar 1 |
2 |
| 8 |
20931330 | Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? | 2011 Jan |
2 |
| 9 |
17908053 | Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. | 2007 Sep |
1 |
| 10 |
19300564 | Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. | 2007 Jun |
1 |
| 11 |
12162759 | Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. | 2002 |
1 |
| 12 |
9839763 | Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. | 1998 Nov |
1 |